Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology [UBX] reported Q3 2024 financial results, highlighting progress in developing UBX1325 (foselutoclax) for diabetic macular edema (DME). Following FDA interaction, UNITY expects a pivotal study to be a non-inferiority trial comparing UBX1325 to aflibercept. Financial highlights include cash position of $29.0 million as of September 30, 2024, net loss of $6.5 million (down from $14.8 million in Q3 2023), and reduced R&D expenses of $2.8 million (down from $4.6 million). The company expects topline 24-week data in Q1 2025 and 36-week data in Q2 2025.
UNITY Biotechnology (NASDAQ: UBX) has announced an in-person and virtual Ophthalmology Day event for investors and analysts on October 15, 2024, in New York. The event will feature presentations from ophthalmology key opinion leaders and company management, focusing on UNITY's ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) against aflibercept in diabetic macular edema (DME).
The agenda includes discussions on the senolytic therapeutic hypothesis, UBX1325 clinical development plan, and a retina expert roundtable. Twenty-four-week safety and efficacy data are expected in Q1 2025, with 36-week data in Q2 2025. The event will address the evolving therapeutic landscape and UBX1325's potential to meet unmet needs in DME. Virtual attendees can access the webcast through UNITY's website, with replays available for 90 days.
UNITY Biotechnology (NASDAQ: UBX), a company focused on developing therapeutics for age-related diseases, has announced its participation in two upcoming investor conferences. The company will provide corporate updates and engage in one-on-one meetings at these events:
1. H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, at 7:00 a.m. ET (virtual presentation)
2. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET in New York, NY
Live webcasts of both presentations will be available through UNITY's website, with archived replays accessible for 90 days after the events. These conferences provide UNITY with opportunities to showcase its progress in developing treatments to slow, halt, or reverse diseases of aging.
UNITY Biotechnology (NASDAQ:UBX) reported its Q2 2024 financial results and provided business updates. Key highlights include:
Enrollment Success: The company exceeded its enrollment goal for the ASPIRE study, evaluating UBX1325 against aflibercept in diabetic macular edema (DME).
Financial Position: Cash, cash equivalents, and marketable securities totaled $34.0 million as of June 30, 2024. UNITY believes this is sufficient to fund operations into Q3 2025.
Reduced Net Loss: Q2 2024 net loss was $5.3 million, down from $15.5 million in Q2 2023.
Decreased Expenses: R&D expenses decreased to $3.5 million from $6.4 million, while G&A expenses reduced to $3.5 million from $5.4 million year-over-year.
Study Timeline: Topline 24-week primary endpoint data for the ASPIRE study is expected in Q1 2025, with 36-week data in Q2 2025.
UNITY Biotechnology, a company focused on developing therapeutics for age-related diseases, has announced the granting of a stock-based award to its new chief strategy officer. The award, approved by the Compensation Committee of the Board of Directors, includes options to purchase 100,000 shares of UNITY common stock and 15,000 Restricted Stock Units. This grant, totaling 115,000 shares, was made under the UNITY 2020 Employment Inducement Incentive Plan, which was established to provide incentives for newly hired employees in accordance with Nasdaq Stock Market Rule 5635(c)(4). The award became effective on July 22, 2024, serving as a material inducement for the new executive to join UNITY.
UNITY Biotechnology [NASDAQ: UBX] has appointed Alicia Tozier, MBA, as Chief Strategy Officer. With 20 years of experience in pharma and medical devices, including a decade in retinal diseases, Tozier will develop and implement corporate and product strategies. Her expertise in ophthalmology product planning and commercial strategy is expected to be important for advancing UBX1325, UNITY's lead program for diabetic macular edema (DME).
Tozier's impressive track record includes leading 18 launches across 8 therapeutic areas in 70 global markets. She previously held senior roles at Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals, and Baxter Healthcare. Her experience in scaling cross-functional teams and executing go-to-market strategies, particularly in ophthalmology, is seen as valuable for UNITY's strategic vision and operational excellence.
UNITY Biotechnology (NASDAQ: UBX) reported its Q1 2024 financial results and business updates on May 14, 2024. The company focuses on therapies to combat aging-related diseases. Significant progress was made in the Phase 2b ASPIRE study of UBX1325 for diabetic macular edema, expanding the study to 50 patients and extending it to 36 weeks for better efficacy assessment. Financials show cash equivalents of $38.3 million, with a net loss of $5.8 million, slightly higher than the $5.3 million in Q1 2023. Cash used in operations decreased significantly from $11.3 million to $5.2 million. R&D and G&A expenses also declined due to study completions, reduced headcount, and sublease income.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
